TAIRX, INC.
- Country
- ๐น๐ผTaiwan
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.trx.com.tw
Study of TRX-920 for Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: TRX-920 Oral Gel (10 mg and 30 mg)
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- TaiRx, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06143774
- Locations
- ๐จ๐ณ
National Cheng-Kung University Hospital, Tainan, Taiwan
๐จ๐ณChina Medical University Hospital, Taichung, Taiwan
๐จ๐ณTaipei Medical University Hospital, Taipei, Taiwan
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
- Conditions
- Advanced CancerHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- TaiRx, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05257590
- Locations
- ๐จ๐ณ
National Taiwan University Hospital, Taipei, Taiwan
๐จ๐ณKaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
๐จ๐ณNational Cheng Kung University Hospital, Tainan, Taiwan
Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients
- Conditions
- Advanced Cancer
- Interventions
- Drug: CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- TaiRx, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04336124
- Locations
- ๐จ๐ณ
National Cheng Kung University Hospital, Tainan, Taiwan
๐จ๐ณChina Medical University Hospital, Taichung, Taiwan
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
- Conditions
- Lung Neuroendocrine NeoplasmNeuroendocrine CarcinomaPancreatic Neuroendocrine TumorNeuroendocrine TumorsGastro-enteropancreatic Neuroendocrine Tumor
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- TaiRx, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03600233
- Locations
- ๐จ๐ณ
New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan
๐จ๐ณChang Gung Memorial Hospital, LinKou, Taoyuan City, Taiwan
๐จ๐ณChang Gung Memorial Hospital, KaoHsiung, Kaohsiung, Taiwan
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
- Conditions
- Hepatocellular CarcinomaAdvanced Cancer
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- TaiRx, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03582618
- Locations
- ๐จ๐ณ
National Taiwan University Hospital, Taipei, Taiwan
๐จ๐ณNational Cheng Kung University Hospital, Tainan, Taiwan
๐บ๐ธCharleston Hematology Oncology Associates, Charleston, South Carolina, United States
Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients
- Conditions
- CarcinomaAdvanced Cancer
- Interventions
- Drug: TRX-818 capsules
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- TaiRx, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT02703298
- Locations
- ๐จ๐ณ
National Cheng Kung University Hospital, Tainan City, Tainan, Taiwan
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
- Conditions
- CarcinomaAdvanced Cancer
- Interventions
- Drug: TRX-818 capsules
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- TaiRx, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02507544
- Locations
- ๐บ๐ธ
South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas, United States
๐บ๐ธSTART Midwest, Grand Rapids, Michigan, United States